Table 1. Baseline characteristics of patients.
| TKI + RT(n = 67) | TKI (n = 66) | P-value | |
|---|---|---|---|
| EGFR Mutation Type, n (%) | 0.336 | ||
| exon 21 substitution | 33 (49.3) | 38 (57.6) | |
| exon 19 deletion | 34 (50.7) | 28 (42.4) | |
| Gender | 0.800 | ||
| male | 30 (44.8) | 31 (47.0) | |
| female | 37 (55.2) | 35 (53.0) | |
| TKI pattens | 0.091 | ||
| gefitinib | 43 (64.2) | 44 (66.7) | |
| erlotinib | 24 (35.8) | 22 (33.3) | |
| KPS | 0.773 | ||
| < 70 | 6 (9.0) | 5 (7.6) | |
| ≥ 70 | 61 (91.0) | 61 (92.4) | |
| Extracranial Metastases | 0.950 | ||
| no | 23 (34.3) | 23 (34.8) | |
| yes | 44 (65.7) | 43 (65.2) | |
| NO. Of Brain Metastases | 0.319 | ||
| 1 to 3 | 18 (26.9) | 23 (34.8) | |
| > 3 | 49 (73.1) | 43 (65.2) | |
| Age | 0.187 | ||
| ≤ 65 | 56 (83.6) | 49 (74.2) | |
| > 65 | 11 (16.4) | 17 (25.8) |
Abbreviations: TKI + RT, tyrosine kinase inhibitors combined with radiation therapy; KPS, karnofsky performance score.